Aiom
Anno I | Numero 5 | Settembre 2016
Comitato scientifico editoriale: Paolo A. Ascierto, Vanna Chiarion-Sileni
Editore: Intermedia – Direttore Responsabile: Mauro Boldrini
 
 
Notizie dalla ricerca

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. We performed multiparameter flow cytometry on freshly isolated metastatic melanomasamples from 2 cohorts of 20 patients each prior to …
Continua a leggere
 
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and other cancers, but robust biomarkers have not been identified. We studied a cohort of patients with metastatic melanoma initially treated with cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) blockade (n = 53) followed by programmed death-1 …
Continua a leggere
 
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organisation of Research and Treatment of Cancer was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. Diagnosis is made clinically using …
Continua a leggere
 
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in patients with advanced melanoma, albeit with more high-grade adverse events. We assessed whether sequential administration ofnivolumab followed by ipilimumab, or the reverse sequence, could improve safety without compromising efficacy. We did this randomised, open-label, phase 2 study at nine academic medical centres in the USA. Eligible patients …
Continua a leggere
 
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
Untreated metastatic uveal melanoma (UM) carries a grave prognosis. Unlike cutaneous melanoma (CM), there are no established treatments known to significantly improve outcomes for a meaningful proportion of patients. Inhibition of the PD1-PDL1 axis has shown promise in the management of CM and we here report a two center experience of UM patients receiving pembrolizumab. To assess the efficacy and safety of pembrolizumab, we retrospectively analyzed outcome data of 25 consecutive UM …
Continua a leggere
 
Appuntamenti AIOM
 
XVIII Congresso Nazionale AIOM
Roma, 28 – 30 ottobre 2016
Link all'evento

 
Nuovi farmaci in oncologia 2016. Valore e sostenibilità
Ferrara, 23 settembre 2016
 
Immunotherapy: Past, Present and Future
Napoli, 26 settembre 2016
 
Immuno-oncologia: Stato dell'arte e update
Bari, 29 settembre 2016
Evento riservato ai Soci della Puglia
 
WISPO 2016
Sperimentazioni Cliniche. Il Nuovo Regolamento Europeo: dalla teoria alla pratica
Milano, 29 settembre 2016
 
Combinazioni e sequenze in terapia: aspetti clinico-metodologici e farmacoeconomici
Roma, 29 – 30 settembre 2016
 
Workshop immuno-oncologia IMI
Modena, 30 settembre – 1 ottobre 2016
 
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà
Milano, 11 ottobre 2016
 
Dialoghi sull'Immunoterapia dei Tumori dell'AIOM Campania
Benevento, 18 ottobre 2016
 
Dialoghi sull'Immunoterapia dei Tumori dell'AIOM Campania
Napoli, 20 ottobre 2016
 
4th International Conference
Translational Research in Oncology
Meldola (FC), 8 novembre 2016
Forlì, 9 – 11 novembre 2016
 
Nuove frontiere diagnostico-terapeutiche nelle neoplasie polmonari, renali e nel melanoma
Varese, 12 novembre 2016

 
Questi e altri appuntamenti si possono consultare sul sito AIOM
www.aiom.it
 

 
Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Per contattare la redazione e commentare le notizie clicca qui: redazione
Per consultare i numeri arretrati della newsletter clicca qui: archivio
Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI

Questo progetto è stato realizzato con il contributo di